FDA
-
-
-
-
-
-
-
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
-
-
-
-
-
-
-
XOMA (XOMA) Announces FDA Approval of MIPLYFFA for Patients with Niemann-Pick Disease Type C
-
-
-
-
-
-
-
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
-
-
-
-
-
-
-
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
-
-
-
-
-
-
-
XOMA (XOMA) Announces $35M Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Trial
-
-
-
-
-
-
-
XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Biosciences
-
-
-
-
-
-
-
Pre-Open Stock Movers 08/25: (ADMS) (XOMA) (KMDA) Higher; (GME) (ULTA) (VEEV) Lower (more...)
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

